+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of intermittent use of elismetrep for treating acute migraine attacks. This Phase 3 study compares two doses of elismetrep, 10 mg and 20 mg, to understand their safety profiles over an average of one year. The study involves adult participants who have previously used elismetrep in an acute treatment trial and met compliance requirements. Participants are randomly assigned to receive either 10 mg or 20 mg of elismetrep taken orally during migraine attacks. The study uses a triple-masked design to ensure unbiased results. The treatment period spans approximately one year, during which safety and adverse events are closely monitored. This includes tracking any adverse events leading to discontinuation or serious adverse events related to the study drug. During the study, participants will complete electronic diaries to record migraine episodes and medication use. They will also attend scheduled visits to assess safety and tolerability, including monitoring for adverse events. The research team will measure the proportion of participants experiencing treatment-emergent adverse events and serious adverse events through study completion. Participants are expected to use a personal smartphone to maintain study diaries and comply with study procedures throughout the study duration.

Age: 18Years +All GendersPhase 3
113 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.

Age: 18Years +All GendersPhase Not Applicable
101 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of elismetrep compared with a placebo for treating acute migraine attacks. This randomized, double-blind, phase III trial is conducted at multiple outpatient centers and sponsored by TriGemX Bio, Inc. The study focuses on adults aged 18 to 75 years who experience moderate to severe migraines lasting 4 to 72 hours, with a history of at least 2 but no more than 10 migraine attacks per month. Participants are randomly assigned to one of three groups elismetrep 10 mg, elismetrep 20 mg, or placebo. All treatments are taken orally during a migraine attack. The trial uses a parallel study design and is triple-blinded to ensure unbiased results. The main study period extends until February 2027, with participants monitored for responses two hours after dosing. During the study, participants will complete questionnaires and use an electronic diary on their smartphones to track migraine symptoms and treatment effects. Researchers will assess outcomes such as pain freedom, relief from bothersome symptoms, and functional disability at two hours post-dose. Additional evaluations include monitoring for adverse events up to eight days after dosing. Participants must follow the study schedule and complete all trial procedures to help assess elismetreps potential as an acute migraine treatment.

Age: 18Years - 75YearsAll GendersPhase 3
113 locations
P

Actively Recruiting

Researchers are evaluating the use of rimegepant for intermittent prevention of menstrual migraine in women aged 18 to 45 who experience migraine attacks related to their menstrual cycle. This Phase 3, double-blind, randomized study compares rimegepant with placebo to assess its efficacy and safety during the peri-menstrual period. The study focuses on migraine frequency and severity in women with a history of menstrual migraine and regular menstrual cycles. Participants receive either rimegepant 75 mg orally disintegrating tablets for 7 days during each peri-menstrual period or a matching placebo, along with standard care for acute migraine treatment as needed. The study treatment cycles are repeated over 5 menstrual cycles in the double-blind treatment phase. The study also includes an acute treatment dosing option with rimegepant as needed. During the study, participants will be monitored for changes in the number of migraine and headache days, use of migraine medications, and functional disability related to migraine. Cognitive function is also assessed. Researchers will conduct evaluations over 5 months, covering 5 menstrual cycles, and measure outcomes related to migraine frequency and severity during the peri-menstrual period. Safety and tolerability will be closely monitored throughout the study.

Age: 18Years - 45YearsFEMALEPhase 3
123 locations
A

Actively Recruiting

Researchers are evaluating adaptive interventions to increase long-term use of buprenorphine in adults with probable opioid use disorder OUD who come to the emergency department ED. This trial uses a two-stage, sequential multiple assignment randomized design to develop the most effective approach. The study aims to compare different treatment strategies to see which helps maintain buprenorphine use longer and delays overdose, self-harm, or death. The trial includes several treatment options. Initially, participants receive either the CA Bridge Model with Substance Use Navigator SUN assisted treatment initiation and linkage to care or the same approach plus immediate telehealth connection to an outpatient provider SUNTeleBridge. Those who do not respond within 90 days are randomized to receive ongoing buprenorphine treatment by an ED-based interim treatment team ED-ITT alone or with added behavioral health support ED-ITTBHS for up to 3 months. Responders receive no further active intervention unless they return to the ED or report stopping buprenorphine. Participants will be monitored for buprenorphine prescription fills over 6 months and tracked for overdose, suicide, self-harm, or death events. Researchers will review prescription records, patient reports, and ED visits to assess treatment adherence and outcomes. The study involves regular follow-up and behavioral health assessments to evaluate the effectiveness of different adaptive treatment strategies over one year.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the use of apixaban compared to aspirin to prevent stroke or death in patients who have had a recent intracerebral hemorrhage ICH and also have atrial fibrillation AF. This phase III randomized, double-blinded trial aims to determine if apixaban is superior in preventing any type of stroke or death, as well as if it leads to better functional recovery measured by the modified Rankin Scale. The study will enroll 700 patients and follow them for 12 to 36 months to assess these outcomes. Participants will be randomly assigned to receive either apixaban or aspirin. Apixaban dosing is typically 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for those meeting specific criteria such as older age, lower body weight, or certain medication use. Aspirin is given once daily at a dose of 81 mg. The study includes a treatment period after recent ICH, with careful monitoring for safety and efficacy. During the study, participants will undergo regular assessments including evaluation of stroke occurrence, death, and changes in functional status using the modified Rankin Scale. Safety and adherence will be monitored throughout the follow-up period, which ranges from 12 months up to 3 years. The research team will collect data to understand the benefits and risks of apixaban versus aspirin in this patient population.

Age: 18Years +All GendersPhase 3
187 locations
P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate whether taking 2 grams of oral azithromycin before labor induction in pregnant women during their third trimester can reduce maternal and newborn infections. The trial focuses on women undergoing induction of labor, a common procedure that has increased recently. Researchers want to see if this antibiotic can help prevent infections like chorioamnionitis, endometritis, and wound infections, improving health outcomes and potentially reducing hospital stays and costs. Participants will be randomly assigned to one of two groups one will receive 2 grams of azithromycin four 500 mg tablets once before labor induction, and the other will receive a placebo of four magnesium oxide tablets once before induction. This is a double-blinded study, meaning neither participants nor researchers know who receives the antibiotic or placebo during the trial. Women in the study will be monitored from the time of labor induction through delivery and for six weeks postpartum. Researchers will assess infection rates using a composite infection measure and track any infections that occur during this period. Safety and health outcomes for both mothers and newborns will be carefully followed to understand the impact of azithromycin given before labor induction.

Age: 18Years - 45YearsFEMALEPhase 1
1 location
V

Actively Recruiting

Researchers are evaluating the FebriDx test to determine how well it distinguishes between bacterial and non-bacterial causes in children aged 2 to 11 years who have a fever and suspected acute respiratory infection. This observational study involves febrile pediatric patients presenting to emergency departments, urgent care centers, or primary care offices. The goal is to assess the tests ability to detect a bacterial systemic immune response compared to expert clinical adjudication using a clinical reference algorithm including pathogen detection and immune response measures. The study involves using the FebriDx device, a rapid lateral flow immunoassay that detects elevated levels of host response proteins Myxovirus resistance protein A MxA and C-reactive protein CRP from a fingerstick blood sample. Children suspected of acute respiratory infection will undergo the FebriDx test during a single visit. The study is blinded and observational without experimental treatments or placebo groups. Participants will be assessed once at enrollment with the FebriDx test and clinical data collection. Researchers will review clinical signs, symptoms, and results from pathogen detection tests such as bacterial culture or multiplex PCR to adjudicate infection status. Follow-up includes a 7-day period to monitor outcomes. The main outcome measure is the performance of the FebriDx test in identifying bacterial infections on the day of testing.

Age: 2Years - 11YearsAll Genders
10 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.

Age: 18Years - 74YearsAll GendersPhase 3
205 locations

1-10 of 12

1